Ottawa Belly Casts

potency

Chemotherapy best second-line option for EGFR wild-type NSCLC By Joanna Lyford.

Finally, safety evaluation found that the frequency of adverse events was comparable in both treatment organizations; neutropenia, neurologic toxicity, alopecia, asthenia, and nausea had been all more prevalent with docetaxel than with erlotinib, while the reverse was true for skin toxicity. There is one treatment-related death in each combined group. Docetaxel was much better than erlotinib for all scientific outcomes. Continue reading